Poster: Tumour-infiltrating immune cell markers
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
List view / Grid view
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
This exclusive interview highlights some of Dr Arthur Suckow’s insights into how his team uses RNA therapies to treat rare diseases such as Charcot-Marie-Tooth 1A.
Researchers have presented comprehensive multi-omic profiles to identify genes, non-coding RNAs, proteins, and plasma metabolites involved in NAFLD-to-NASH progression.
Japanese researchers showed for the first time processes that are crucial targets for treating liver cancer are enhanced by saturated fatty acid diets.
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
Measure protein, DNA and RNA in FFPE tissue samples using rigorously IHC validated CST antibodies on the NanoString® nCounter® platform.
US scientists have developed a potential medication for the genetic cause of ALS and dementia, that eliminates the mutated segments of RNA.
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
US researchers identified that those with ADHD have differences in gene activity in the brain.
Sloan Kettering Institute (SKI) researchers have developed a new machete technique to slice into the cancer genome and study copy number alterations.
Researchers have found peptides that bind to chains of ubiquitin proteins in cancer cells, suggesting they could be used as a therapeutic strategy.
US researchers, using genome sequencing, put forward the Nile rat as the new model organism for diabetes research.
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.